

Electronic Patient-Reported Outcome–Based Interventions for Palliative Cancer Care: A Systematic and Mapping Review

Christina Karamanidou, PhD¹; Pantelis Natsiavas, MSc, MEng¹; Lefteris Koumakis, PhD²; Kostas Marias, PhD²; Fatima Schera, BEng³; Michael Schäfer, BSc³; Sheila Payne, PhD⁴; and Christos Maramis, PhD¹

PURPOSE Capitalizing on the promise of patient-reported outcomes (PROs), electronic implementations of PROs (ePROs) are expected to play an important role in the development of novel digital health interventions targeting palliative cancer care. We performed a systematic and mapping review of the scientific literature on the current ePRO-based approaches used for palliative cancer care.

METHODS Following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses statement guidelines, the conducted review answered the research questions: “What are the current ePRO-based approaches for palliative cancer care; what is their contribution/value in the domain of palliative cancer care; and what are the potential gaps, challenges, and opportunities for further research?” After a screening step, the corpus of included articles indexed in PubMed or the Web of Science underwent full text review, which mapped the articles across 15 predefined axes.

RESULTS The corpus of 24 mapped studies includes 9 study protocols, 7 technical tools/solutions, 7 pilot/feasibility/acceptability studies, and 1 evaluation study. The review of the corpus revealed (1) an archetype of ePRO-enabled interventions for palliative cancer care, which most commonly use ePROs as study end point assessment instruments rather than integral intervention components; (2) the fact that the literature has not fully embraced the modern definitions that expand the scope of palliative care; (3) the striking shortage of promising ubiquitous computing devices (eg, smart activity trackers); and (4) emerging evidence about the benefits of narrowing down the target cancer population, especially when combined with modern patient-centered intervention design methodologies.

CONCLUSION Although research on exploiting ePROs for the development of digital palliative cancer care interventions is considerably active and demonstrates several successful cases, there is considerable room for improvement along the directions of the aforementioned findings.

JCO Clin Cancer Inform 4:647-656. © 2020 by American Society of Clinical Oncology

INTRODUCTION

Globally, between 40 and 80 million patients with advanced disease need access to palliative care,¹ which focuses on improving pain and symptom management, reducing psychosocial distress, offering spiritual support, and enhancing quality of life (QoL) for patients and their families.² Initially associated with fatal illnesses (eg, hospice care), especially in the United States, the scope of palliative care has recently become wider. For instance, the latest WHO definition describes palliative care as a health care service that tackles the problems associated with life-threatening illness,² whereas the Centre to Advance Palliative Care distinguishes palliative care from end-of-life care, hospice care, and bereavement care, because the former is appropriate at any age and at any stage in a serious illness and can be provided alongside curative treatment.³

With this in mind, the World Health Assembly⁴ resolution called on governments to integrate palliative care into national health systems throughout a patient’s life cycle and throughout the disease trajectory. To achieve these aims, excellent assessment of patient-reported outcomes (PROs) is required.⁵ PROs are defined as measurements reported directly from the patient about their health status without amendment or interpretation by a physician or anyone else.⁶ With the increasing availability of handheld and wearable electronic devices, greater Internet connectivity, and digital health, electronic patient-reported outcomes (ePRO) have emerged as a feasible option for improving the quality of assessment, and they are expected to play an important role in the development of new digital health interventions that target the palliation of patients with chronic ailments, critically including cancer,

ASSOCIATED CONTENT

Data Supplement

Author affiliations and support information (if applicable) appear at the end of this article.

Accepted on June 5, 2020 and published at ascopubs.org/journal/cci on July 22, 2020; DOI <https://doi.org/10.1200/CCI.20.00015>

CONTEXT

Key Objective

The current systematic review presents the state of the art of electronic implementations of patient-reported outcome (ePRO)–based digital health interventions and highlights the contribution of such interventions to palliative cancer care. A timely addition to an area of growing research interest, this review identifies the challenges and opportunities in the field of digitally enabled delivery of palliative care and provides concrete recommendations for future research.

Knowledge Generated

The proposed digital health interventions have been evaluated positively by end-users with respect to usability, user acceptance, and satisfaction, with few concerns. Existing findings demonstrate that ePRO interventions could have a significant positive impact on health outcomes. Because of the methodologic diversity of the reviewed studies, the precise impact cannot be fully ascertained as yet.

Relevance

The clinical practice of palliative care can be facilitated or promoted through the use of digital health systems leveraging ePROs throughout the trajectory of cancer.

a diverse group of largely chronic diseases that often have a relapsing course.

An indicative example is provided by MyPal,⁷ a recently funded research program aimed at exploiting ePROs for the development of novel palliative care services for patients with cancer across Europe. Using digital health technologies, MyPal aims to empower patients with cancer and their caregivers by more accurately capturing their symptoms/conditions, communicating them effectively to their health care providers (HCPs) and, ultimately, fostering the time for action through the prompt identification of important deviations in the patient's health state and QoL.⁸

Obviously, designing effective digital palliative care interventions for patients with cancer on the basis of ePRO systems relies, among other things, on a thorough appreciation and assessment of the relevant state of the art, representing the motivation and focus of the current systematic and mapping review.⁹ For this reason, we conducted a systematic and mapping review to address the following research questions: “What are the current ePRO-based approaches for palliative cancer care; what is their contribution/value in the domain of palliative cancer care; and what are the potential gaps, challenges, and opportunities for further research?” Given the emergence of numerous palliative care definitions, the current review opts for adopting the widest in scope, covering the entire care continuum for patients with cancer as well as cancer survivors; the adopted palliative care definition greatly overlaps with supportive care.¹⁰

METHODS

This systematic review was conducted according to the guidelines of the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement.^{11,12} The PRISMA checklist is presented in the Data Supplement. The review protocol is outlined in the current section; it has not been registered in any review protocol repository.

Initially, a list of potentially relevant articles was retrieved from online bibliographic sources (Search Strategy), and 3 of the authors independently assessed the eligibility of each article (Inclusion and Exclusion Criteria) on the basis of the information contained in the article title and abstract, whenever possible. The screening was performed with BibReview software.¹³ Next, the eligible literature corpus was mapped across a set of axes that were defined by the reviewing team (Mapping Axes). The corpus was partitioned on the basis of the main focus of the study by the 3 authors involved in the first phase, and each part was assigned to a pair of authors for full text review and mapping. A stylesheet file with columns matching the mapping axes was designed for the reviewing authors to extract the study data; the completed stylesheet files were subsequently merged and manually harmonized by the 3 main authors. Appropriate measures were taken to mitigate the risk of bias (Risk of Bias and Mitigation Measures).

Search Strategy

Two reference bibliographies, namely PubMed¹⁴ and Web of Science,¹⁵ were queried. Given that the scope of the review was targeting ePRO systems and, thus, the focus of the study was primarily technical, these 2 databases were considered adequate.

In the retrieval stage, semantically identical (although appropriately formulated) queries were defined and executed for each bibliographic source. These are provided in the Data Supplement. The last search in both sources was performed on June 10, 2019.

Inclusion and Exclusion Criteria

The selection of the corpus of eligible articles for review has relied on the following criteria. No constraints on the publication year of the studies were applied.

Inclusion criteria. We included articles referring to the implementation and/or deployment of ePRO-based systems

(IC1) for the provision of palliative/supportive care (IC2) to patients with cancer (IC3); these had to be journal articles (IC4) written in English (IC5).

Exclusion criteria. We excluded review, opinion, or editorial articles (EC1), articles referring to the same approach/system (EC2), and articles in which the ePROs were not part of a health care intervention (EC3; eg, studies that collected ePRO data for the sole purpose of statistical analysis).

Mapping Axes

The eligible articles were qualitatively and quantitatively mapped across a number of mapping criteria/axes. These were defined on the basis of the expertise of the authors in

digital health systems and palliative care, as well as on the particular focus of the MyPal program; iterative fine-tuning of the mapping axes was performed as the outcomes from the articles were gradually obtained to ensure that the axes were orthogonal (ie, nonoverlapping) to the greatest extent possible. The final list of mapping axes that was used in the study is provided in [Table 1](#).

Risk of Bias and Mitigation Measures

In the context of this review, bias is defined as a systematic error, or deviation from the truth, in results or inferences.¹⁶ The main identified sources of bias and the way that the study protocol has mitigated the respective risks are as follows:

TABLE 1. Mapping Axes Specified by the Review Protocol

Mapping Axis		Axis Outline
MA1	Bibliometrics	Eg, year published, journal, country, author organization types: they have been used to provide an overall picture of the work performed on the domain and highlight the involvement of various stakeholders in the conducted research
MA2	Main focus of the study	A single main focus topic for each study has been selected to be able to categorize them using one of the following values: evaluation, impact assessment, presentation of measure/scale/pro, protocol, technical tool/solution, pilot/feasibility/acceptability study
MA3	Link with palliative care	A free-text field highlighting the link, the contribution, or the potentials of each presented work regarding the overall domain of palliative cancer care
MA4	ICT system components	Identifies the use of specific ICT components on each presented work in an abstract fashion; on the basis of this, 2 other mapping fields are populated (ie, ICT application types and ICT device types)
MA5	ICT application types	An enumerated field identifying the categories of software applications used in each intervention, using the following categories: Web application, mobile application, desktop application
MA6	ICT device types	An enumerated field identifying the categories of hardware devices used in each intervention, using the following categories: tablets, smart phones, computers, smart watches, smart TVs, body sensors
MA7	Intervention	A free-text field describing the intervention presented in each work
MA8	Population	Describes the patients engaged in each intervention, focusing on eligibility criteria and related aspects; the “age category” field is extracted on the basis of this field
MA9	Age category	Identifies the patient age categories focused on in each study, categorizing them using the values “children,” “adolescents,” “adults”
MA10	Disease focus	Depicts the main medical focus of the respective study; on the basis of this information, 2 categorization fields were defined (ie, malignancy category and cancer type)
MA11	Malignancy category	Identifies whether the main focus of the work refers to solid tumors or hematologic cancers
MA12	Cancer type	Identifies the explicit cancer types that are elaborated on in each study
MA12	Key findings	A free-text field describing the main contribution(s) of each paper
MA13	ePRO added value	A free-text field describing the contribution of ePRO systems in the overall intervention
MA14	Lessons learned/strengths/weaknesses	A free-text fields categorizing the key aspects of each work
MA15	How does it fit into MyPal	A free-text field identifying potential links between the study and the MyPal project

NOTE. For the studies with main focus “study protocol,” the mapping axes MA12 and MA14 were left uncompleted.

Abbreviations: ePRO, electronic implementations of patient-reported outcome; ICT, information and communication technology.

Reporting bias is related to the selection of the findings to be presented in a study. Because there is no widely accepted methodology for publishing the results of ePRO interventions, the reviewed studies report results in an arbitrary manner, which could affect the review outcomes. To tackle this source of bias, the review protocol refrained from synthesizing quantitative results reported by the reviewed studies.

Competing interests bias does not exist for the authors of the current review study. However, the authors of some of the reviewed articles are affiliated with industry, which could introduce some level of bias in the reported outcomes. The authors with competing interests with industry were identified; they account for 25% of the reviewed studies.

Evidence selection bias occurs when important research is not identified by the review (eg, research not published because of a lack of statistical significance in the results). To mitigate this risk, 2 widely used reference bibliographic sources (Search Strategy) were used by the review protocol, increasing the search space and, consequently, the chances of articles in this category being published. However, a residual risk remains, which is acceptable in the context of the current work.

RESULTS

This section provides the main findings of this systematic and mapping review. After presenting the outcome of the study selection (Study Selection) and the characteristics of the included studies (Study Characteristics), the remainder

of the section summarizes the mapping analysis along a short list of composite mapping axes/directions. The complete data set of the mapping outcome for all the included studies is available in the Data Supplement.

Study Selection

In total, the corpus of included articles consisted of 24 studies.¹⁷⁻⁴⁰ The PRISMA flow diagram depicting the overall study selection process is presented in Fig 1.

Study Characteristics

The characteristics of the 24 included studies were extracted from the data that were collected with respect to the bibliometric mapping axis (MA1), and they are presented in Table 2.

Publications timeline. Figure 2A presents the distribution of the included studies per publication year, demonstrating the gradual building of a critical mass of studies involving ePROs for palliative cancer care. This distribution seems to be compatible with the picture of a research topic in the making.

Target journals. A wide range of scientific journals (n = 15) has been targeted by the included studies. In this regard, the most prominent targets were *BMJ Open*⁴¹ (n = 5) and *Supportive Care in Cancer*⁴² (n = 3), with the rest of the journals publishing 1 or 2 studies. The distribution of the included studies per publishing journal is presented in Fig 2B.

Geographic distribution. The geographic distribution of the included studies was extracted at the country level on the

FIG 1. Preferred Reporting Items for Systematic Reviews and Meta-Analyses flow diagram of the conducted systematic review. PRO, patient-reported outcome.




TABLE 2. Bibliometric Characteristics of the Included Studies

First Author	Year	Journal	Country	Organization Type
Gressel ¹⁷	2019	Gynecologic Oncology	United States	Academia/research, health care
Ciani ¹⁸	2019	BMJ Open	Italy, United Kingdom	Academia/research, health care
Phillips ¹⁹	2019	Trials	Australia	Academia/research
Wright ²⁰	2018	JCO Clinical Cancer Informatics	United States	Academia/research
Girgis ²¹	2018	BMC Cancer	Australia	Academia/research, health care
Soh ²²	2018	JMIR mHealth and uHealth	Republic of Korea	Industry, health care, academia/research
Allsop ²³	2018	BMJ Open	United Kingdom	Academia/research, health care
Song ²⁴	2018	JMIR research protocols	United States	Academia/research, health care
Melissant ²⁵	2018	Acta Oncologica	Sweden	Academia/research, health care
Benze ²⁶	2019	Annals of Palliative Medicine	Germany	Academia/research, health care, industry
Langius-Eklöf ²⁷	2017	BMC Cancer	Sweden	Academia/research
Maguire ²⁸	2017	BMJ Open	United Kingdom, Ireland, United States, Greece, Austria, Norway, Belgium	Academia/research, health care, industry
Duman-Lubberding ²⁹	2015	Journal of Medical Internet Research	Netherlands, United Kingdom	Academia/research
Dussel ³⁰	2015	Journal of Pain and Symptom Management	United States, Argentina, Australia	Academia/research, health care
Wagner ³¹	2015	Cancer	United States	Academia/research
Maguire ³²	2015	Cancer Nursing	United Kingdom, Denmark	Academia/research, patient organizations
Gustavell ³³	2019	Cancer Nursing	Sweden	Academia/research
Akechi ³⁴	2018	Bmj Open	Japan	Academia/research, health care, industry
Jibb ³⁵	2017	Pediatric Blood & Cancer	Canada	Academia/research, health care
Sundberg ³⁶	2017	Supportive Care in Cancer	Sweden	Academia/research
Schuler ³⁷	2017	BMJ Open	Germany	Academia/research, health care
Trautmann ³⁸	2016	Supportive Care in Cancer	Germany	Academia/research, health care
Kallen ³⁹	2012	Supportive Care in Cancer	United States	Academia/research, industry
Dy ⁴⁰	2011	Journal of Pain and Symptom Management	United States	Academia/research, health care, industry

basis of the affiliation origin of all the authors of each study; this means that a study could be assigned to multiple countries. In brief, one third of the studies ($n = 8$) derived from the United States, whereas other countries with strong contributions on the topic included the United Kingdom ($n = 5$), Sweden ($n = 4$), Australia ($n = 3$), and Germany ($n = 3$). Of note, when combined, the European countries accounted for 83.3% ($n = 20$) of the included studies. Five studies were international.

Organization types. The review categorized the potential organization types of the author affiliations for the included studies as academia/research, health care, and industry. From the data in Table 2, one can observe that the academia/research organizations participated in the entirety of the study, followed by health care organizations ($n = 15$) and then industry ($n = 6$). During the mapping process, the need to extend the list of potential organization types to include patient organizations ($n = 1$) emerged. It should also be noted that no policy-making or regulatory organizations

were identified as contributors in the included study corpus, indicating a potential gap in the interaction of academia, health care, and industry with the aforementioned organizations.

Study Focus

The main focus of each included study (ie, the primary aspect of the ePRO-based intervention that was presented in the articles) has been identified by MA2 and presented in Fig 3. Most of the articles present study protocols ($n = 9$), whereas technical tools/solutions ($n = 7$) and pilot/feasibility/acceptability studies ($n = 7$) are also common.

It should be noted that only the main focus of the respective studies is depicted in this figure and that many of them could be considered to cross-cut these categories. For example, many of the reviewed studies present a feasibility study of a specific technical tool, while also evaluating it in terms of its impact assessment.




FIG 2. Selected aggregated bibliometric characteristics of the included studies. (A) By publication year. (B) By journal.

Target Populations

Several mapping axes (MA8-MA12) depict the characteristics of the target populations engaged in the respective ePRO-based interventions.

Age category. The vast majority of the interventions ($n = 22$) targeted adults, whereas 2 interventions were designed for adolescents. Only 1 intervention targeted children, indicating a significant gap in the literature and also a potential research opportunity.

Disease focus. Apart from a number of studies that report interventions addressing cancer in general ($n = 10$), most of the included studies were more focused on the disease of the target population. All 24 studies report on interventions designed for patients with solid tumors, whereas 10 of these studies address hematologic malignancies as well. In more detail, the great majority of the included studies target specific cancer types (eg, prostate cancer [$n = 3$], lung cancer [$n = 2$], GI cancer [$n = 1$], head and neck cancer

[$n = 1$], pancreatic cancer [$n = 1$], and sarcoma [$n = 1$], as well as the family of gynecologic cancers, including breast cancer [$n = 6$]). It should be noted, however, that some interventions focus on more than 1 malignancy and/or cancer type.

Users' perspective. The analysis of strengths and weaknesses of the digital health solutions proposed by each study (MA14) provides valuable information about the respective end-users. The proposed digital health solutions have been evaluated positively through a variety of methods by end-users with respect to usability, user acceptance, and satisfaction. System adoption and usage,^{25,31} as well as attitudes toward recommending²⁰ or reusing the system,²⁶ have often been used. Certain widespread pre-existing (ie, System Usability Scale),³⁹ or adapted measures^{18,30,34} have also been reported. Finally, interviews with actors (patients, HCPs, caregivers) have been conducted with the intention of exploring facilitators, barriers, and suggestions for improvement.²¹ Future research should offer recommendations for reliable ways of ePRO-based digital health systems evaluation, thus facilitating comparability among studies.

In rare cases, participants raised serious concerns. One article reported that the use of a system was a “barrier,”³⁵ whereas in another, one half of clinicians doubted the system’s clinical usefulness and viewed it as an addition to their workload.³² However, the majority of reviewed studies presented solutions assisting HCPs go through a large amount of data quickly (ie, by adopting a traffic light system in which only red flags require attention)³⁶ or incorporate self-care components for patients to use on their own at home).²⁰ This transition may not always be smooth, but it has become absolutely paramount, considering the growing number of patients with cancer worldwide requiring supportive care.

One of the most important lessons learned from the study of the user perspective in the reviewed articles is that additional improvement regarding information and communication technology (ICT) components and user interaction is needed.^{22,25,26,29,32,33,38} The need for improvement with respect to overall symptoms management has also been reported by some studies.^{32,33,35,36}




FIG 3. Main focus of the included studies.

offer new capabilities for monitoring/tracking the physiological status of the patient.

Strengths and Weaknesses

The most commonly identified methodologic strengths of the reviewed literature include (1) participatory design (ie, involvement of important actors²⁹ during eHealth system development); (2) multicenter, randomized controlled trials (RCTs) of adequate duration and sample size²⁸ that usually preceded a feasibility or pilot study²⁰; (3) interventions developed and/or performed by a multidisciplinary palliative care team and addressing multiple aspects of palliative care^{23,32,38}; (4) use of validated ePROs measuring symptoms, QoL, and supportive care needs¹⁸; and (5) evaluation of the eHealth system regarding usability and user satisfaction.²⁶

The most commonly identified methodologic weaknesses include (1) the exclusion of patients who were not technologically apt²¹; (2) the monitoring of symptoms not followed by an action (ie, a call from the health care professional)²⁶; and (3) the inability to attribute outcomes changes to specific components of complex multifactorial interventions.³⁴

DISCUSSION

For the most part, the reviewed literature indicates that palliative care tends to be associated with advanced cancer stages, which suggests insufficient digital health research embracing the current definition of palliative care. The aim of future studies should be to assess the applicability and effectiveness of digital health interventions developed for patients with cancer in need of palliation in its wider scope. Specifically, they should aim to facilitate or promote the delivery of palliative care from the point of diagnosis and throughout the continuum of the disease.

The review of the existing literature also disclosed 2 distinct ways that ePROs can be used in the context of digital health studies: (1) as assessment instruments for the end points of a clinical study, which is the most common ePRO use case, and (2) as a building block of a digital health intervention, which is less common but better promotes the integration of ePROs into routine clinical practice. Indeed, the role of ePROs in the former case ends as soon as the assessment of the digital health solution is completed, whereas in the latter case, they constitute an integral part of a real-life digital health product. In a few of the reviewed studies, ePROs served both purposes.

A common pattern emerges from the literature about the structure of digital health interventions for palliative cancer care. In brief, the following workflow is adopted by the archetypical digital health palliative cancer care intervention: (1) ePRO data on disease-related symptoms are collected; (2) the patient gets value from the ePRO data in the context of self-care: this can entail acting on self-care advice provided via the digital health system or the patient is empowered to monitor their own health status and make informed decisions about their care in collaboration with the health care team; (3) the collected ePRO data are

presented to the health care professional(s), in real time if possible; and (4) the health care professional(s) review the data and take action, if needed (eg, tailor the treatment/medication to the patient on the basis of symptom severity or bothersomeness, contact the patient, and so forth).

Other common themes identified within the reviewed interventions include (1) the integration of intelligent modules and/or system-initiated actions in the presented digital health systems, mainly in the form of dynamic evidence-based self-care feedback provided after ePRO completion and alert service notifications for health care professionals; and (2) statements that the proposed digital health solutions are not emergency services, in line with the current rationale of palliative care.

One exemplary study is eSMART, a multicenter RCT aiming to evaluate an electronic symptom management system for patients with cancer.²⁸ Appropriate ePROs will be part of the intervention, leveraged to elicit patients' chemotherapy-related symptoms, leading to evidence-based, self-care feedback and automatic alerts for HCPs. Furthermore, ePROs will also be used for the intervention end points' evaluation, namely, reduced symptom burden and anxiety and supportive care needs, as well as improved self-care efficacy and QoL. Cost-effectiveness and potential changes to clinical practice will also be considered. Another pragmatic study is LuCApp, an RCT aiming to evaluate a mobile supportive care app for patients with metastatic lung cancer.¹⁸ In this case, ePROs are part of the intervention and the evaluation process. Patients report symptom incidence, and HCPs are alerted if severity overcomes specific thresholds. Evaluation is conducted in terms of QoL impact, supportive care needs, caregiver burden, and resource use.

The reviewed studies have not taken advantage of recent advances in wearables (ie, smart watches or smart wristbands), which could nicely complement ePROs. This is surprising, given the share of such devices in the consumer electronics market and their adoption in telehealth care solutions. The designers of future palliative cancer care services could benefit from advancements in wearable technologies by integrating them into the digital health system they intend to develop.

Finally, the published evidence indicates not only that patients with cancer are generally in favor of ePRO-based interventions, but also that ePRO interventions could contribute to improved health outcomes such as an improvement in physical activity²⁰; a reduction in anxiety and drowsiness³²; lower levels of fatigue, nausea, insomnia,³⁶ and pain intensity; as well as a significant improvement in emotional and social functioning.³⁵

Nonetheless, the review gives rise to a clear demand for improvements in the designed digital health systems on the basis of patient needs. With this in mind, research has to be narrowed down as much as possible to a target population and digital health solutions must be adapted to the specific

user group needs (eg, in terms of usability), thus increasing efficiency. Indeed, most of the reviewed studies have endorsed this logic, as evidenced by their choice of patient populations with specific characteristics (eg, specific age groups and cancer types; see Target Populations).

For future digital health approaches in palliative cancer care, a good understanding of the particular needs of the target population is paramount. This can be acquired with the help of modern participatory design tools, such as surveys and focus groups with representatives from the target patient population and expert palliative cancer care practitioners.

Although the strong adherence to PRISMA guidelines ensures that the review has been conducted on a solid methodologic ground, there is also 1 important limitation: the included studies were methodologically diverse (including unfinished

lines of research such as protocols and pilot/feasibility studies), meaning that the full impact of ePRO interventions on health outcomes cannot yet be fully ascertained.

The conducted review revealed that scientific research on the exploitation of ePROs for developing digital palliative cancer care interventions is active and demonstrated a number of successful cases, while also highlighting significant room for research. Using the aforementioned successful cases as a guide, future research efforts should strategically enhance the state of the art in palliative cancer care ePRO systems and digital health services in general to facilitate the information flow between patients and health care experts and eventually close the information loop, which is of paramount importance for the vision of P4 Medicine,⁴⁷ especially its last 2 dimensions.

AFFILIATIONS

¹Institute of Applied Biosciences, Centre for Research and Technology Hellas, Thessaloniki, Greece

²Institute of Computer Science, Foundation for Research & Technology Hellas, Heraklion, Greece

³Fraunhofer Institute for Biomedical Engineering IBMT, St Ingbert, Germany

⁴International Observatory on End of Life Care, Lancaster University, Lancaster, United Kingdom

CORRESPONDING AUTHOR

Christos Maramis, PhD, Institute of Applied Biosciences, Centre for Research & Technology Hellas, Thessaloniki, Greece; e-mail: chmaramis@certh.gr.

SUPPORT

Supported by the European Union's Horizon 2020 Research and Innovation Programme Grant No. 825872. The funder played no role in the systematic review.

AUTHOR CONTRIBUTIONS

Conception and design: Christina Karamanidou, Christos Maramis

Collection and assembly of data: Christina Karamanidou, Pantelis Natsiavas, Lefteris Koumakis, Kostas Marias, Fatima Schera, Michael Schäfer, Christos Maramis

Data analysis and interpretation: Christina Karamanidou, Pantelis Natsiavas, Sheila Payne, Christos Maramis

Manuscript writing: All authors

Final approval of manuscript: All authors

Accountable for all aspects of the work: All authors

AUTHORS' DISCLOSURES OF POTENTIAL CONFLICTS OF INTEREST

The following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated unless otherwise noted. Relationships are self-held unless noted. I = Immediate Family Member, Inst = My Institution. Relationships may not relate to the subject matter of this manuscript. For more information about ASCO's conflict of interest policy, please refer to www.asco.org/rwc or ascopubs.org/cci/author-center.

Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians ([Open Payments](http://OpenPayments)).

No potential conflicts of interest were reported.

ACKNOWLEDGMENT

We acknowledge the contribution of the late Vassilis Koutkias, PhD, in the conceptualization, design, and implementation of the current review.

REFERENCES

1. Knaul FM, Farmer PE, Krakauer EL, et al: Alleviating the access abyss in palliative care and pain relief—an imperative of universal health coverage: The Lancet Commission report. *Lancet* 391:1391-1454, 2018
2. Sepúlveda C, Marlin A, Yoshida T, et al: Palliative care: The World Health Organization's global perspective. *J Pain Symptom Manage* 24:91-96, 2002
3. Get Palliative Care: What is palliative care? <https://getpalliativecare.org/whatis/>
4. World Health Assembly: (2014). WHA67.19 Strengthening of palliative care as a component of comprehensive care throughout the life course. In Sixty-seventh World Health Assembly. Retrieved from https://apps.who.int/iris/bitstream/handle/10665/162863/A67_R19-en.pdf?sequence=1&isAllowed=y
5. Bausewein C, Daveson BA, Currow BC, et al: EAPC White paper on outcome measurement in palliative care: improving practice, attaining outcomes and delivering quality services – Recommendations from the European Association for Palliative Care (EAPC) Task Force on Outcome Measurement. *Palliat Med* 30:6-22, 2016
6. LeBlanc TW, Abernethy AP: Patient-reported outcomes in cancer care - hearing the patient voice at greater volume. *Nat Rev Clin Oncol* 14:763-772, 2017
7. MyPal: Fostering palliative care of adults and children with cancer through advanced patient reported outcome systems. <https://mypal-project.eu/>
8. Maramis C, Karamanidou C, Schera F, et al: Using electronic patient reported outcomes to foster palliative cancer care: The MyPal Approach. IEEE 19th International Conference on Bioinformatics and Bioengineering (BIBE), Athens, Greece, October 28-30, 2019
9. Grant MJ, Booth A: A typology of reviews: An analysis of 14 review types and associated methodologies. *Health Info Libr J* 26:91-108, 2009
10. Radbruch L, Payne S: White paper on standards and norms for hospice and palliative care in Europe: Part 1. *Eur J Palliat Care* 16:278-289, 2009

11. Moher D, Liberati A, Tetzlaff J, et al: Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement. *Ann Intern Med* 151:264-269, W64, 2009
12. Liberati A, Altman DG, Tetzlaff J, et al: The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: Explanation and elaboration. *Ann Intern Med* 151:W65-W94, 2009
13. Lamy J-B, Séroussi B, Griffon N, et al: Toward a formalization of the process to select IMIA Yearbook best papers. *Methods Inf Med* 54:135-144, 2015
14. PubMed – National Center for Biotechnology Information. <https://www.ncbi.nlm.nih.gov/pubmed/>
15. Web of Science. <https://clarivate.com/webofsciencegroup/solutions/web-of-science/>
16. Higgins JPT, Altman DG: Assessing risk of bias in included studies, in Higgins JPT, Green S (eds): *Cochrane Handbook for Systematic Reviews of Interventions: Cochrane Book Series*, 2008.
17. Gressel GM, Dioun SM, Richley M, et al: Utilizing the Patient Reported Outcomes Measurement Information System (PROMIS®) to increase referral to ancillary support services for severely symptomatic patients with gynecologic cancer. *Gynecol Oncol* 152:509-513, 2019
18. Ciani O, Cucciniello M, Petracca F, et al: Lung Cancer App (LuCApp) study protocol: A randomised controlled trial to evaluate a mobile supportive care app for patients with metastatic lung cancer. *BMJ Open* 9:e025483, 2019
19. Phillips JL, Heneka N, Lovell M, et al: A phase III wait-listed randomised controlled trial of novel targeted inter-professional clinical education intervention to improve cancer patients' reported pain outcomes (The Cancer Pain Assessment (CPAS) Trial): Study protocol. *Trials* 20:62, 2019
20. Wright AA, Raman N, Staples P, et al: The HOPE Pilot Study: Harnessing patient-reported outcomes and biometric data to enhance cancer care. *JCO Clin Cancer Inform* 2:1-12, 2018
21. Girgis A, Durcinoska I, Geroges M, et al: Study protocol for a controlled trial of an eHealth system utilising patient reported outcome measures for personalised treatment and care: PROMPT-Care 2.0. *BMC Cancer* 18:845, 2018
22. Soh JY, Cha WC, Chang DK, et al: Development and validation of a multidisciplinary mobile care system for patients with advanced gastrointestinal cancer: Interventional observation study. *JMIR Mhealth Uhealth* 6:e115, 2018
23. Allsop MJ, Wright-Hughes A, Black K, et al: Improving the management of pain from advanced cancer in the community: Study protocol for a pragmatic multicentre randomised controlled trial. *BMJ Open* 8:e021965, 2018
24. Song L, Dunlap KL, Tan X, et al: Enhancing survivorship care planning for patients with localized prostate cancer using a couple-focused mHealth symptom self-management program: Protocol for a feasibility study. *JMIR Res Protoc* 7:e51, 2018
25. Melissant HC, Verdonck-de Leeuw IM, Lissenberg-Witte BI, et al: 'Oncokompas', a Web-based self-management application to support patient activation and optimal supportive care: A feasibility study among breast cancer survivors. *Acta Oncol* 57:924-934, 2018
26. Benze G, Nauck F, Alt-Epping B, et al: PROtline: A feasibility study assessing surveillance of electronic patient reported outcomes and adherence via smartphone app in advanced cancer. *Ann Palliat Med* 8:104-111, 2019
27. Langius-Eklöf A, Craford M-T, Christiansen M, et al: Effects of an interactive mHealth innovation for early detection of patient-reported symptom distress with focus on participatory care: Protocol for a study based on prospective, randomised, controlled trials in patients with prostate and breast cancer. *BMC Cancer* 17:466, 2017
28. Maguire R, Fox PA, McCann L, et al: The eSMART study protocol: A randomised controlled trial to evaluate electronic symptom management using the advanced symptom management system (ASyMS) remote technology for patients with cancer. *BMJ Open* 7:e015016, 2017
29. Duman-Lubberding S, van Uden-Kraan CF, Peek N, et al: An eHealth application in head and neck cancer survivorship care: Health care professionals' perspectives. *J Med Internet Res* 17:e235, 2015
30. Dussel V, Orellana L, Soto N, et al: Feasibility of conducting a palliative care randomized controlled trial in children with advanced cancer: Assessment of the PediQUEST study. *J Pain Symptom Manage* 49:1059-1069, 2015
31. Wagner LI, Schink J, Bass M, et al: Bringing PROMIS to practice: Brief and precise symptom screening in ambulatory cancer care. *Cancer* 121:927-934, 2015
32. Maguire R, Ream E, Richardson A, et al: Development of a novel remote patient monitoring system: The advanced symptom management system for radiotherapy to improve the symptom experience of patients with lung cancer receiving radiotherapy. *Cancer Nurs* 38:E37-E47, 2015
33. Gustavell T, Langius-Eklöf A, Wengström Y, et al: Development and feasibility of an interactive smartphone app for early assessment and management of symptoms following pancreaticoduodenectomy. *Cancer Nurs* 42:E1-E10, 2019
34. Akechi T, Yamaguchi T, Uchida M, et al: Smartphone problem-solving and behavioural activation therapy to reduce fear of recurrence among patients with breast cancer (SMartphone Intervention to LEssen fear of cancer recurrence: SMILE project): Protocol for a randomised controlled trial. *BMJ Open* 8:e024794, 2018
35. Jibb LA, Stevens BJ, Nathan PC, et al: Implementation and preliminary effectiveness of a real-time pain management smartphone app for adolescents with cancer: A multicenter pilot clinical study. *Pediatr Blood Cancer* 64:e26554, 2017
36. Sundberg K, Wengström Y, Blomberg K, et al: Early detection and management of symptoms using an interactive smartphone application (Interaktor) during radiotherapy for prostate cancer. *Support Care Cancer* 25:2195-2204, 2017
37. Schuler M, Richter S, Ehninger G, et al: A cluster-randomised, controlled proof-of-concept study to explore the feasibility and effect of a patient-directed intervention on quality of life in patients with advanced soft tissue sarcoma. *BMJ Open* 7:e014614, 2017
38. Trautmann F, Hentschel L, Hornemann B, et al: Electronic real-time assessment of patient-reported outcomes in routine care—first findings and experiences from the implementation in a comprehensive cancer center. *Support Care Cancer* 24:3047-3056, 2016
39. Kallen MA, Yang D, Haas N: A technical solution to improving palliative and hospice care. *Support Care Cancer* 20:167-174, 2012
40. Dy SM, Roy J, Ott GE, et al: Tell Us™: a Web-based tool for improving communication among patients, families, and providers in hospice and palliative care through systematic data specification, collection, and use. *J Pain Symptom Manage* 42:526-534, 2011
41. *BMJ Open*. <https://bmjopen.bmj.com/pages/>
42. Springer: Supportive Care in Cancer. <https://www.springer.com/journal/520>
43. Laranjo L, Dunn AG, Tong HL, et al: Conversational agents in healthcare: A systematic review. *J Am Med Inform Assoc* 25:1248-1258, 2018
44. Johnson D, Deterding S, Kuhn K-A, et al: Gamification for health and wellbeing: A systematic review of the literature. *Internet Interv* 6:89-106, 2016
45. Barth L, Fabrikant SI, Kobourov SG, et al: Semantic Word Cloud Representations: Hardness and Approximation Algorithms, in Pardo A, Viola A (eds): *LATIN 2014: Theoretical Informatics*. Berlin/Heidelberg Germany, Springer, 2014, pp 514-525
46. spupyrev: spupyrev/swcv. <https://github.com/spupyrev/swcv>
47. Hood L, Flores M: A personal view on systems medicine and the emergence of proactive P4 medicine: Predictive, preventive, personalized and participatory. *N Biotechnol* 29:613-624, 2012

